Changes in Specific Immunoglobulin and Blood Basophil Activity During Subcutaneous Immunotherapy in Allergic Rhinitis
Changes in Specific Immunoglobulin and Blood Basophil Activity During Subcutaneous Immunotherapy in Patients With Allergic Rhinitis Due to Grass Pollen Allergy - a Prospective Randomized Controlled Study
The trial is randomized prospective study to examine the effects of subcutaneous immunotherapy on the adaptive immune system. The trial includes 30 participants randomized to treatment or control group. The effect measures are changes in the basophil activity and biology as well as changes in plasma cells during and after treatment. Clinical outcome is assessed by QoL questionnaires and clinical testing.
Hypotheses:
- changes in plasma cells correlate to changes in immunoglobulins and effector cell responses
- the reduction of inflammation due to SCIT has influence on the effector cell responses
- changes in paraclinical measurements can be related to clinical findings
調査の概要
状態
条件
詳細な説明
The investigators are recruiting 30 participants, which are randomized to receive SCIT (24) or no treatment (6) The following will be measured
- the development of immunoglobulin response
- plasma cells under updosing phase
- changes in basophil activity under updosing and maintenance treatment
- subtyping of allergic sensitization
- clinical outcome and quality of life
- changes in mast cells in the nasal mucosa
- changes in the cell biology of the basophils
研究の種類
入学 (実際)
段階
- 適用できない
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- rhinoconjunctivitis due to grass pollen allergy
- positive skin prick test and nasal allergen challenge test to grass pollen extract
Exclusion Criteria:
- severe comorbidity, severe asthma, pregnancy
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:基礎科学
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ:alutard phl prat. treatment group
18 subjects receiving active treatment: basophil activity, plasma cells and immunoglobulins measured
|
standard regimen of SCIT
他の名前:
他の名前:
|
|
介入なし:control group
control
|
|
|
アクティブコンパレータ:alutard phl.prat., treatment group2
basophil activity, basophil biology measured
|
standard regimen of SCIT
他の名前:
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
a significant decrease in basophil activity during and after treatment
時間枠:every 3 weeks for 3 months, then 3 monthly for 3 years
|
every 3 weeks for 3 months, then 3 monthly for 3 years
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
reduction in high affinity IgE receptor density on basophils and mast cells
時間枠:at inclusion and at the end of study
|
igE receptor density on basophils and mast cells from nasal mucosa
|
at inclusion and at the end of study
|
|
clinical outcome: reduction in the reaction to allergen challenge tests (skin and nose), significant better outcome in quality of life questionnaires and symptom/medication scores
時間枠:once yearly for 4 years
|
allergen challenging response
|
once yearly for 4 years
|
|
a significant increase in the number of plasma cells during up dosing
時間枠:5 times during the first 3 months of the study
|
5 times during the first 3 months of the study
|
|
|
a significant shift in specific immunoglobulins from IgE at start to IgG1 and IgG4 after treatment. allergen epitope specific IgE and IgG4
時間枠:every 3 months for 4 years
|
every 3 months for 4 years
|
協力者と研究者
捜査官
- スタディチェア:Ronald Dahl, Prof, dr.med、Dept. of Respiratory Medicine, Århus University Hospital
- 主任研究者:Hans Juergen Hoffmann, assoc prof、Dept of Respiratory Medicine, Århus University Hospital
- 主任研究者:Johannes M Schmid, MD、Dept. of Respiratory Medicine, Aarhus University Hospital
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。